Study S000472

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)

ClinicalTrials.gov record

Registration

Registration: NCT05295875
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 391
Start: 2022-03-31
Primary completion: 2023-09-28
Lead sponsor: Altimmune, Inc.
Conditions: Obesity/Overweight
Interventions: DRUG:ALT-801; OTHER:Placebo
Results posted: FALSE

Registered primary outcomes

Relative change from baseline in body weight percentage [Baseline to Week 48]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.